3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Neoplasms
5
Lung Neoplasms
4
Glioblastoma
3
Urinary Bladder Neoplasms
2
Glioma
2
Brain Neoplasms
2
Astrocytoma
2
Uterine Cervical Neoplasms
1
Tuberculosis, Pulmonary
1
Thyroid Nodule
1
Stomach Neoplasms
1
Solitary Pulmonary Nodule
1
Pulmonary Fibrosis
1
Pulmonary Embolism
1
Pulmonary Disease, Chronic Obstructive
1
Pulmonary Arterial Hypertension
1
Pleural Neoplasms
1
Pancreatic Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Multiple Pulmonary Nodules
1
Mesothelioma
1
Lung Injury
1
Lung Diseases, Interstitial
1
Lung Diseases
1
Lung Abscess
1
Esophageal Neoplasms
1
Emphysema
1
Disease
1
Cystic Fibrosis
1
Colorectal Neoplasms
1
Interventions
fluciclovine F-18
2
Positron-Emission Tomography
2
Injections
2
Dexamethasone
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
tislelizumab
1
technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid)
1
ricolinostat
1
pomalidomide
1
pembrolizumab
1
lortalamine
1
gossypol acetic acid
1
daratumumab
1
aflibercept
1
Prednisone
1
Oncolytic Virotherapy
1
Octreotide
1
Mitomycin
1
Mammography
1
Lenalidomide
1
Ipilimumab
1
Drug Delivery Systems
1
Docetaxel
1
Diagnosis, Computer-Assisted
1
Daunorubicin
1
Cytarabine
1
Control Groups
1
CPX-351
1
Bevacizumab
1
Antibodies, Monoclonal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Disease
×
Drug Delivery Systems
×
Clear all
NCT01373671
2020-08-07
DBT
Siemens Medical Solutions USA - CSG
Phase NA
Completed
764 enrolled
5 charts